SELLAS Life Sciences Group Inc buy melinda
Summary
This prediction ended on 19.07.16 with a price of €10,913. The prediction had a final performance of 16.22%. melinda has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
SELLAS Life Sciences Group Inc | 0.923% | 0.923% | -22.301% | -86.835% |
iShares Core DAX® | 3.054% | -1.396% | 15.789% | 12.675% |
iShares Nasdaq 100 | 4.389% | -5.391% | 29.906% | 39.325% |
iShares Nikkei 225® | 5.386% | -3.105% | 16.065% | 8.150% |
iShares S&P 500 | 2.955% | -3.011% | 25.903% | 37.650% |
Comments by melinda for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
erwartete Zunahme
Anteile von Galena Biopharma sind fast 80% im vorbörslichen Handel fallen. GALE: ein 1-Jahres - Hoch von $ 2,49 und einem 1-Jahres - Tief von 0,59 $. Die 50-Tage-Aktie gleitenden Durchschnitt ist 1,86 $ und seine 200-Tage - Durchschnitt beträgt $ 1,30.
Stopped prediction by melinda for SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group Inc
08.09.20
04.11.21
05.11.21
SELLAS Life Sciences Group Inc
09.11.18
13.11.18
13.11.18
SELLAS Life Sciences Group Inc
15.10.18
07.11.18
07.11.18
SELLAS Life Sciences Group Inc
31.08.18
01.10.18
01.10.18